Trial Profile

Clinical study of carelizumab combined with apatinib and irinotecan in the second-line treatment of advanced esophageal squamous cell carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Irinotecan (Primary) ; Rivoceranib (Primary)
Indications Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

30 May 2025 New trial record
09 May 2025 Results published in the BMC Cancer
09 May 2025 Status changed to completed as per results published in the BMC Cancer

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com